We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ILU:ASXIluka Resources Limited Analysis

Data as of 2026-08-24 - not real-time

A$7.35

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Iluka Resources Limited trades at AUD 7.35, with its short-term moving averages stacked above the longer-term ones — a bullish trend structure. It has gained 13.6% over the past 30 days. Momentum indicators put RSI at 61.5 (approaching overbought) with MACD reading bullish. Watch AUD 5.75 as support and AUD 7.49 as the nearer resistance level.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Analyst price targets sit 9.2% above the current price. Revenue is contracting at 21.1% on a -45.2% profit margin. The 0.86% dividend yield looks covered by current payout levels.
Risk comes out at 8 of a possible 10, a high reading. With 30-day volatility of 45.1%, a beta of 1.04 and a maximum drawdown of 46.8%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
The horizons line up on hold — conviction 2 out of 10.

Top Market Events

Iluka Resources ASX:ILU reports lower mineral sands revenue in H1 2026 but advances Eneabba rare earths refinery and...Iluka Resources Q1 2026 saw lower revenue and production, but major minerals and rare earths projects continue to...Shareholders in Iluka Resources Limited ASX:ILU may be thrilled to learn that the analysts have just delivered a.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 3/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • Trading above the 200-day average of 6.73
  • MACD momentum is positive

Medium Term

1–3 years
Neutral
Model confidence: 1/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • Trading above the 200-day average of 6.73
  • Analyst targets imply +9.2% versus the current price

Long Term

> 3 years
Neutral
Model confidence: 2/10

Key Factors

  • Negative profit margin of -45.2%
  • Analyst targets imply +9.2% versus the current price
  • Negative return on equity of -18.0%

Key Metrics & Analysis

Financial Health

Revenue Growth-21.10%
Profit Margin-45.25%
P/E Ratio-24.8
ROE-18.00%
ROA-2.86%
Debt/Equity62.99
P/B Ratio1.6
Op. Cash FlowA$190.1M
Free Cash FlowA$-411312512

Technical Analysis

TrendBullish
RSI61.5
SupportA$5.75
ResistanceA$7.49
MA 20A$6.82
MA 50A$6.82
MA 200A$6.73
MACDBullish
VolumeDecreasing
Fear & Greed Index94.41

Valuation

Fair ValueA$1.09
Target PriceA$8.03
Upside/Downside9.18%
GradeFair
TypeBlend
Dividend Yield0.86%

Risk Assessment

Beta1.04
Volatility45.07%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.